Quick Answer
Enliven Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $98.90 million for the year ending 2025.
- Enliven Therapeutics, Inc. showed a decrease of -20.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Enliven Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $48.90 million | Q2 2019: $45.23 million | Q3 2019: $17.09 million | Q1 2020: $86.72 million | Q2 2020: $54.65 million | Q3 2020: $34.16 million | Q1 2021: $53.44 million | Q2 2021: $48.04 million | Q3 2021: $75.30 million | Q1 2022: $99.88 million | Q2 2022: $92.46 million | Q3 2022: $86.16 million | Q1 2023: $292.10 million | Q2 2023: $125.72 million | Q3 2023: $73.85 million | Q1 2024: $149.17 million | Q2 2024: $96.87 million | Q3 2024: $100.62 million | Q1 2025: $101.71 million | Q2 2025: $119.44 million | Q3 2025: $101.73 million.
- Over the full 7 years of available data (2019 to 2025), Enliven Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,903.6%.
- Historical annual values: Fiscal year 2025: $98.90 million | Fiscal year 2024: $124.12 million | Fiscal year 2023: $100.14 million | Fiscal year 2022: $75.54 million | Fiscal year 2021: $48.31 million | Fiscal year 2020: $47.70 million | Fiscal year 2019: $4.94 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: